Th1Th17_CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment

Table 1

Clinical and demographic characteristics of MS patients included in the study.

	Total cohort ()	Relapsed () ()	Nonrelapsed (NR) ()	DMF cohort ()	FNG cohort ()
Female sex (no. of patients (%))	42 (63)	12 (57)	30 (67)	15 (68)	26 (59)
Age (years), mean (SD)
First symptoms (years), mean (SD)
Previous immunomodulatory drugs	33 naïve	11 naïve	22 naïve	15 naïve	18 naïve
	16 IFN-β	4 IFN-β	12 IFN-β	4 IFN-β	12 IFN-β
	3 GA	1 GA	2 GA		3 GA
	10 NTZ	3 NTZ	7 NTZ		10 NTZ
	1 diazoxide		1 diazoxide		1 diazoxide
	1 teriflunomide			1 teriflunomide
	1 fingolimod			1 fingolimod
	1 others			1 others
Number of previous treatments (years), mean (SD)
0 treatment	33	13	20	15	18
1 treatment	16	4	12	4	12
2 treatments	12	5	7	1	11
≥3 treatments	5	2	3	2	3
ARR previous year
Total patients	1.53 (1.1)	1.53 (1.2)	1.52 (0.8)	1.14 (0.7)	1.53 (1.13)
Naïve patients	1.54 (0.9)	1.55 (1.1)	1.6 (0.8)	1.6 (0.8)	1.61 (1.20)
Treated patients	1.5 (1.3)	1.6 (1.5)	1.3 (1)	1.3 (1)	1.52 (1.21)

DMF: dimethyl fumarate; FNG: fingolimod; IFN-β: interferon beta; GA: glatiramer acetate; NTZ: natalizumab; others: clinical trial of cell therapies; ARR: annualized relapse rate; SD: standard deviation.